The locomotor hyperactivity induced by 3,4-methylene dioxymethamphetamine (MDMA) and related drugs in rats appears to be due to the drug-induced release of presynaptic serotonin (5-HT). Thus, these drugs increase locomotor activity by acting as indirect 5-HT agonists.
to placement in the test chambers. As previously reported for MDMA, locomotor activity increased with dose, and investigatory rearings and holepokes decreased. These findings confirm the similarity between the behavioral effects of RU 24969 and indirect 5-HT agonists and suggest that the locomotor hyperactivity produced by both RU 24969 and MDMA is mediated by the activation of 5-HT1B receptors. Although the effects of MDMA on 5-HT1B receptors are secondary to its ability to release presynaptic 5-HT, the activation produced by RU 24969 appears to be a consequence of its direct agonist effects. [Neuropsychopharmacology 8:201-211, 1993J Although central serotonergic systems have long been thought to exert inhibitory influences on motoric be havior (Soubrie 1986) , recent studies have demonstrated that the predominant effect of indirect serotonin (5-HT) agonists in rats is a profound locomotor activation. The locomotor hyperactivity produced by 3,4-methylene dioxymethylamphetamine (MDMA) and related drugs is not due primarily to dopamine (DA) release, but is attributable instead to the release of presynaptic 5-HT.
First, studies using the Behavioral Pattern Monitor 0893-133X/93/$6.00 (BPM) to characterize the behavioral profIle produced by indirect 5-Hf agonists revealed that the hyperactivity produced by these drugs is qualitatively different from that produced by amphetamine-like stimulants acting via DA release (Gold et al. 1988) . Second, the MDMA induced hyperactivity can be prevented by pretreat ment with selective 5-HT uptake blockers, including fluoxetine, sertraline, and zimelidine, or with the 5-Hf synthesis inhibitor parachlorophenylalanine (Callaway et al. 1990) . By contrast, these pretreatments either potentiate or have no effect on the hyperactivity in duced by the DA-releasing agent amphetamine. Third, the catecholamine synthesis inhibitor a-methyl-p-tyro sine blocks the locomotor activating effects of amphet amine but does not affect the response to MDMA (Cal laway et al. 1990 ). Fourth, congeners of MDMA that lack the ability to release DA although retaining the abil ity to release 5-HT also produce marked increases in locomotor activity in rats (Callaway et al. 1991a (Callaway et al. , 1991b Paulus and Geyer 1992) . For example, N-methyl-1-(1,3-benzodioxol-5yl)-2-butanamine (MBDB), a derivative of MDMA that releases 5-HT without releasing DA or blocking DA reuptake, produced a dose-dependent and MDMA-like locomotor activation that was completely blocked by pretreatment with fluoxetine (Callaway et al. 1991a) . Parallel biochemical data conbrm that fluox etine prevents the depletions of brain 5-HT induced acutely by MDMA or MBDB (Callaway et al. 1991a) . Therefore, the acute motor-activating properties of these compounds appear to result from facilitating the release of presynaptic 5HT.
Given that these methylenedioxy-substituted phenyl alkylamines increase locomotor activity by acting as in direct 5-HT agonists, the question arises as to the 5-HT receptor subtype upon which this released 5-HT acts postsynaptically to produce this effect. Serotonin recep tors are classifIed as 5-HTI and 5-HT2 (Peroutka and Snyder 1979) and at least three subtypes, 5-HTIA, 5-HT18, and 5-HTlC have been characterized in rats (Pedigo et al. 1981; Hoyer et al. 1985; Peroutka 1986 ). When tested under conditions in which MDMA in creases locomotion, direct agonists at both 5-HTIA and 5-HTlC/2 receptors consistently decrease locomotor ac tivity. Specibcally, both full and partial 5-HT lA agonists, including 8-0H-DP AT, bus pirone, gepirone, and ipsapirone, produce dose related and robust reduc tions in both locomotor and investigatory responses in the BPM (Mittman and Geyer 1989) . In addition, both l-(m)-chlorophenyl-piperazine and l-(m)-trifluoro methylphenyl-piperazine, putative 5-Hf 1C agonists (Hoyer 1988) , also decrease horizontal locomotion (MA Geyer, unpublished results; Lucki 1989) . Similarly, di rect agonists at 5-HflC/2 receptors, including quipazine and both indoleamine and phenethylamine hallucino gens, also decrease activity in the BPM, at least when the animals are not familiar with the test environment NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.3 (Adams and Geyer 1985a, b; Wing et al. 1990 ). These effects of the direct agonists are selectively antagonized by the appropriate 5-HTI or 5-HTlC/2 antagonists and can be differentiated behaviorally using the profIle of measures provided by the BPM system (Mittman and Geyer 1989; Wing et al. 1990 ). Hence, it seems unlikely that the hyperactivity produced by the indirect agonists reflect an activation of postsynaptic 5-HflA' 5-HfIe, or 5-HT 2 receptors.
By contrast, systemic administration of the 5-HTlB agonist 5-methoxy-3(l, 2, 3, 6)tetrahydropyridin-4-yl)-1H-indole (RU 24969) has been shown to increase loco motor activity in rodents (Oberlander and Boissier 1981; Green et al. 1984) apparently by acting at postsynaptic 5-HT18 receptors (Tricklebank et al. 1986; Oberlander et al. 1987 ). This effect involves coordinated forward locomotion and is readily distinguishable from the myoclonic syndrome produced by some other 5-HT agonists (Green et al. 1984) . The agonist RU 24969 has been shown to have a high affmity for both the 5-HTlA and 5-HT18 sites with some selectivity for the 5-HTIB site (Sills et al. 1984; Doods et al. 1985) . Because the 5-HT 18 site is the only characterized 5-HT receptor as sociated with increased locomotor activity, it is a likely candidate as the site of action of the endogenous 5-HT released by indirect 5-HT agonists such as MDMA. Therefore, the present study was designed to charac terize the hyperactivity produced by RU 24969 by ex amining patterns of locomotor and investigatory be havior in the BPM in order to compare its effects with those of the indirect 5-HT agonists in the same experi mental paradigm. Additional pharmacologic studies were conducted to corroborate evidence that the be havioral effects of RU 24969 are due to its 5-HTIB agonist actions at postsynaptic sites. SpecifIcally, it was hypothesized that the behavioral profIle produced by RU 24969 would mimic that characteristic of indirect 5-HT agonists, including increased locomotor activity dominated by straight paths of movement in both direc tions around the BPM chamber, decreased investiga tory holepoking, and decreased rearing behavior. Such a behavioral profIle would distinguish the activating effects of RU 24969 from those produced by scopola mine, caffeine, nicotine, and direct or indirect DA agonists (Geyer et al. 1986 ).
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Harlan Labs, Indianapolis, IN) weighing between 250 and 400 g were housed in pairs and maintained in a temperature-and light controlled environment on a reversed-light cycle (lights on from 1900 to 0700). Except during behavioral test ing, animals were given free access to food and water.
In total, 78 animals were used, each animal being tested only once.
Behavioral Measures
Behavior was measured in a BPM system designed to monitor behavioral patterns as described previously (Geyer et al. 1986 ). Briefly, the BPM chamber is a30. 5 x 61 cm black Plexiglas box with three floor holes and seven wall holes, each equipped with an infrared pho tobeam for the detection of holepokes. A 4 x 8 grid of photobeams is used to defIne the position of the ani mal in an x-y coordinate system with a resolution of 3.8 cm. Rearing against the chamber walls is detected by a touch-plate 15.2 cm above the floor. Chambers are kept dark with the exception of 7.5 watt red light bulbs.
A computer monitors the status of all photobeams and records the duration and nature of all changes with a te mporal resolution of 55 msec. Horizontal locomo tion is recorded as crossings, a measure of movement between photobeam-defIned sectors. Holepokes are recorded as repeated holepokes (pokes occurring at the same hole in a single bout of investigation) or varied hole pokes (the initial poke in a bout of investigation). Total holepokes are presented when measures of re peated and varied holepokes show the same effect. Rearings are similarly divided into varied and repeated rearings and presented in the same manner as hole pokes. The number of entries into the center region is corrected for activity level by dividing by the total num ber of crossings and is presented as a center entries to crossings ratio. The spatial character of locomotor ac tivity can also be visualized by means of graphical recon structions of the animal's path during the session. Ad di tional measures utilized to describe locomotor path are the CV9 and d statistics. The CV9 evaluates the se quences of position change by calculating the number of occurrences of each of the 40 possible transitions be tween 9 chamber regions (center, 4 corners, and 4 mid wall regions [see Geyer 1990] ). An increase in CV9 reflects the tendency to repeat certain paths or region transitions. The sequence of the x-y positions is used to ca lculate the d statistic; increases or decreases in d reflect a rougher or smoother path, respectively. Briefly, d, the spatial scaling exponent, is based on the fact that the measured length of a line depends upon the length of the ruler used for the measurement. Hence, d reflects the slope of the line relating the measured length to the ruler size. Increases or decreases in d reflect a rougher or smoother path, respectively. After indirect 5-HT agonists are administered, CV9 is increased (Gold et al. 1988 ) and d is decreased (Callaway et al. 1991b; Pau lus and Geyer 1991; Paulus and Geyer 1992) reflecting the relatively predictable and straight locomotor paths ex hibited by the drug-treated animals. For each experimental session, naive animals were brought to the laboratory under a black cloth at least 1 hour prior to testing. Following the appropriate phar macologic manipulation, each animal was gently placed into a chamber. Data were collected for 120 minutes dur ing the dark phase of the animals' light I dark cycle. The chambers were cleaned thoroughly between testing ses sions.
Drug Treatments
The RU 24969 succinate (Roussel-Uclaf, Romainville, France), (+ I -)propranolol HCl, (+ )propranolol HCl (Research Biochemicals Inc., Natick, NJ), and ( + )MDMA HCl (NIDA, Rockville, MD) were dissolved in saline and injected subcutaneously in a volume of 1 ml/kg of body weight. Fluoxetine HCl (Lilly, Indianapolis, IN) was dissolved in saline for intraperitoneal injections in a volume of 2 ml/kg of body weight. Twenty-four rats received RU 24969 at doses of 0, 1.25, 2.5, or 5 mg/kg (0. 0044, 0.0087, or 0.0174 mmollkg). The 2.5 mg/kg dose, which increased locomotor activity signifIcantly but submaximally, was used for assessments of drug interactions. Pretreatments with (+ I -)propranolol (20 mg/kg or 0.0676 mmollkg) and (+ )propranolol (10 mg/kg or 0.0338 mmollkg) were administered 30 min utes prior to an injection of RU 24969 or saline. Fluoxe tine (10 mg/kg or 0.0289 mmollkg) injections were given 50 minutes before RU 24969 or saline. All animals were placed in the testing chambers 10 minutes after the fInal drug treatment. Each experimental group consisted of six rats.
Data Analysis
Crossings, center entries, hole pokes, and rearings were examined in 10-, 30-, or 60-minute intervals, as appro priate. Statistical comparisons were performed using repeated-measures analysis of variance (ANOV A) (Dixon 1988) . Post-hoc comparisons were made using Tukey's Studentized Range Method on 30-minute blocks of data. The d statistic was analyzed by ANOV A on the fIrst 60 minutes of data. Comparisons for CV9 data were made using the Mann-Whitney U-test.
RESULTS
Dose Response
As summarized in Table 1 , RU 24969 dramatically al tered the behavioral activity profi.le of rats. A signifIcant effect of RU 24969 dose on crossings was found for the 2-hour test session (F[3,20] = 26.87, P < .0001). As shown in Figure 1 , horizontal locomotion was increased Data are expressed as group means ± SEM, with the exception of the CV9 statistic, which is ex pressed as median values.
* p < 0.05 relative to saline controls by Tukey's tests following signifIcant ANOVA. ** P < 0.01 relative to saline controls by Tukey's tests following signifIcant ANOV A.
dose dependently, with the largest effects being pro duced by the 2.5 and 5 mg/kg doses. Levels of activity in rats treated with high doses of RU 24969 remained elevated during the 2nd hour of testing, whereas the activity of control animals decreased across time. Hence, the interaction between time and drug was signiftcant (F[33,220] = 5.95, P < .0001). The activity produced by 2.5 and 5 mg/kg doses of RU 24969 at the end of the 2-hour session was still greater than that of the control animals at any time.
In addition to increasing locomotor activity, RU 24969 induced changes in investigatory behavior. The effects of RU 24969 on total holepokes are detailed in Table 1 . Despite the increases in activity produced by RU 24969, total holepokes were decreased signiftcantly, especially by the higher doses. Repeated holepokes were decreased signifIcantly by RU 24969 throughout the test session (F[3,20] = 5.82 P < .005). Although the total number of varied holepokes was not decreased by RU 24969, the interaction between time and drug was signifIcant (F[33,220] = 2.33, P < .0005). Control animals had high levels of investigatory holepokes for the frrst 30 minutes of testing, which decreased as they habituated to the chambers. In contrast, rats at the 2.5 and 5 mg/kg doses of RU 24969 exhibited an initial de crease in total and varied holepokes, but the rate of var ied holepokes did not decrease with time. As shown in Table 1 , RU 24969 (1.25 to 5 mg/kg) caused a pro nounced decrease in rearing behavior (for 0 to 120 minutes, F[3,20] = 17.84, P < .0001). At the two highest doses, virtually no rearing occurred during the 2-hour test session. Both repeated and varied rearings were decreased similarly by RU 24969.
The spatial patterns of locomotion were altered dra matically by RU 24969. At high doses (2.5 to 5 mg/kg), animals typically avoided the center of the testing cham ber and walked or ran along the walls. This pattern is illustrated for a typical animal in Figure 2 . For compari son purposes, the patterns exhibited by a representa tive control animal and an animal treated with 10 mg/kg 
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by RU 24969, resulting in a signifIcant pretreatment by-drug interaction across the entire session (F[3,20] = 22.1, p< .00(1). Racemic propranolol alone had no effect on locomotor activity.
By contrast, there was no signifIcant pretreatment by-drug interaction between racemic propranolol and RU 24969 for the number of holepokes (F[3,20] = 0, ns) (Table 2) . Likewise, racemic propranolol failed to an tagonize the RU 24969-induced suppression of rearings (for 0 to 120 minutes: F[3,20] = .6, ns), although the interaction between time and drug was signifIcant (for o to 120 minutes: F[33,220] = 2.69, P < .005) ( Table 2 ).
In keeping with its ability to antagonize the loco motor activating effects of RU 24969, racemic propran olol antagonized the RU 24969-induced tendency to Figure 3 . Graph illustrating crossings after saline or 2.5 mg/kg RU 24969, with saline or 20 mg/kg ( + I -)propranolol pretreatment are shown as group means ± SEM for succes sive 30-minute intervals. (+ I -)propranolol signifIcantly re duced the hyperactivity produced by RU 24969. This experi· ment was run concurrently with the RU 24969 dose-response study. Hence, the 2. 5 mg/kg RU 24969 group was the same as that shown in Figure 1 and Table 1 . Data are expressed as group means ± SEM. * P < 0.05 relative to saline controls by Tukey's tests following signifrcant ANOVA. ** P < 0.01 relative to saline controls by Tukey's tests following signifrcant ANOVA.
MINUTE BLOCKS
• SALINE 
Fluoxetine and RU 24969 Interaction
As reported previously (Callaway et al. 1990 ), fluoxe tine pr etreatment alone had no effect on the behaviors measured. Fluoxetine pretreatment did not affect RU 24969-induced behavioral activity. Figure 5 shows the failure of fluoxetine to antagonize the locomotor acti vation produced by RU 24969, despite the effectiveness of this dose of fluoxetine in blocking the effects of MDMA in this paradigm (Callaway et al. 1990 ). Simi larly, no signifIcant interactions between fluoxetine and RU 24 969 were found for holepokes, rearings, center to-crossings ratio, or center entries (Table 3) . 
MINUTE BLOCKS
4 Figure 5 . Graph illustrating crossings after saline or 2. 5 mg/kg RU 24969, with saline or 10 mg/kg fluoxetine pretreat ment are shown as group means ± SEM for successive 30-minute intervals. Fluoxetine had no signifIcant effect on the hyperactivity produced by RU 24969. This experiment was run concurrently with the RU 24969 dose-response and ( + /-)propranolol studies. Hence, the 2. 5 mg/kg RU 24969 group was the same as that shown in Figure 1 and Table 1 and the saline/saline group was the same as that shown in Figure 3 and Table 2 . Data are expressed as group means ± SEM.
* P < 0.05 relative to saline controls by Tukey's tests following signifIcant ANOVA. ** P < 0.01 relative to saline controls by Tukey's tests following signifIcant ANOVA. In addition to the qualitative similarities between the locomotor activity patterns produced by RU 24969
and indirect 5-HT agonists, both similarly decrease in vestigatory behaviors, including both holepokes and rearings. Treatment with MDMA depresses initial lev els of total holepokes, which then rise or remain the same across a 120-minute testing session, u nlike con trol animals that exhibit fewer holepokes over time (Gold et al. 1988) . The level of total holepokes follow ing RU 24969 administration has the same pattern of initially decreased levels that remain constant across time. The effect of high doses of MDMA on rearing is to decrease rearing initially with a subsequent although variable increase over time (Gold et al. 1988) . Similarly, RU 24969 depresses the initial number of rearings but to a greater extent than MDMA, and no increase in rear ings is observed during a 120-minute test session.
As discussed previously with regard to MDMA (Gold et al. 1988) , the profIle of behavioral changes fol lowing RU 24969 is distinct from that produced by other stimulant drugs. Throughout a wide range of dos es, amphetamine, which induces behavioral activation via DA release in the mesolimbic pathway (Kelly et al. 1975) , produces highly varied patterns of locomotor and investigatory behavior, characterized by concomi tant increases in locomotion, holepokes, and rearings (Geyer et al. 1987) . The hyperactivity induced by MDMA and RU 24969 is accompanied by decreases in investigatory responses. Whereas the activity engen dered by MDMA and RU 24969 is primarily along the walls with directional changes typically occurring only when a corner is encountered, amphetamine produces increased locomotion that is distributed throughout all regions of the chamber and includes frequent direc tional changes (Geyer et al. 1987) . Hence, RU 24969 and MDMA increase and amphetamine decreases the CV9 measure of the predictability of the pattern (Geyer et al. 1986; Gold et al. 1988 ). In addition, both RU 24969
and MDMA produce relatively straight paths and there-fore decrease the d statistic (Paulus and Geyer 1992) ; however, amphetamine does not aff ect this measure except at high doses when d is increased (Paulus and Geyer 1991) . Thus, although manipulations of central DA systems have been shown to affect the response toRU 24969 (Green et al. 1984; Tricklebank et a1. 1986; Uchitomi and Yamawaki 1988) , it is probable that RU 24%9 activation is not a direct result of DA release. Simi lar conclusions have been reached by Oberlander et al. (1986) . Like MDMA and RU 24969, the direct DA agonist apomorphine decreases holepokes and rearings, but produces only weak and variable stimulation of loco motor activity characterized by unidirectional circling patterns (Geyer et al. 1987) . The cholinergic antagonist scopolamine also produces a form of hyperactivity dominated by movements around the perimeter of the chamber, but it increases investigatory responding at the same time (Geyer et al. 1986 ). Caffeine also increases investigatory responding together with increases in locomotor activity (Geyer et al. 1986 ).
The qualitative similarity in locomotor patterns and activity between MDMA and RU 24969 suggests that these drugs exert their behavioral effects by means of closely related mechanisms, presumably within the 5-HT system. The locomotor hyperactivity induced by MDMA and related drugs such as parachloroamphet amine, MBDB, and methylenedioxyamphetamine is due to release of presynaptic 5-HT (Callaway et al. 1990; Cal laway et al. 1991a ). Accordingly, the locomotor activat ing effects of these indirect 5-HT agonists are prevented by pretreatment with the 5-HT synthesis inhibitor parachlorophenylalanine or by administration of 5-HT uptake inhibitors such as fluoxetine, zimelidine, or ser traline (Callaway et al. 1990 (Callaway et al. , 1991a . By contrast, the effects of RU 24969 are insensitive to parachlorophen ylalanine (Green et al. 1984; Uchitomi and Yamawaki 1988) or fluoxetine (present study). These results are consistent with the hypothesis that the effects of RU 24969 are mediated by postsynaptic rather than pre synaptic serotonergic mechanisms. This hypothesis is further corroborated by evidence indicating that the effects of RU 24969 are not reduced and are typically enhanced by neurotoxic lesions of 5-HT neurons in duced by 5,7-dihydroxytryptamine (Nisbet and Mars den 1984; Oberlander et al. 1986 Oberlander et al. , 1987 Tricklebank et aI. 1986 ). Thus, it appears that RU 24969 produces hyperactivity by acting via a postsynaptic 5-HT recep tor, possibly the same 5-HT receptor upon which the endogenous 5-HT released by MDMA must act.
As summarized above, direct agonists at 5-HT 1A or 5-HTlC/2 receptors suppress rather than increase loco motor activity in this paradigm (Mittman and Geyer 1989; Wing et al. 1990) . Hence, the hypothesis tested in these studies was that the 5-HTlB receptor might mediate the activating effects of the indirect 5-HT agonists. Although considerable biochemical evidence RU 24969-Induced Hyperactivity 209 suggests that the 5-HT1B receptor contributes impor tantly to the effects ofRU 24969 (Sills et al. 1984; Doods et al. 1985) pharmacologic evidence for the selective effects of RU 24969 at the 5-HT1B site is somewhat in consistent (Tricklebank et al. 1986) . In the present studies, the racemic form of propranolol antagonized the locomotor activation of RU 24969 but had minimal effects by itself and did not influence the ability of RU 24969 to decrease investigatory behavior. These results are consistent with the similar influences of racemic pro pranolol on the effects of MDMA (Callaway et al. 1992) . Thus, the present results with racemic propranolol pro vide additional evidence for a commonality in the mech anisms of action of RU 24969 and the indirect 5-HT agonists. However, in previous studies, both the (+) and ( -)isomers of propranolol have been found to sup press RU 24969-induced hyperactivity (Trickle bank et al. 1986 ), a result that is inconsistent with evidence for selective antagonism of 5-HTI sites by (-)propranolol (Middlemiss 1985) . A preliminary report of apparently comparable studies provides some evidence for a stereo selective antagonism of the effects of RU 24969 by pro pranolol (Mylecharane et al. 1991) . The isomer (-)pro pranolol but not ( + )propranolol inhibits the behavioral responses produced by other drugs acting at 5-HT1 receptors (Green and Grahame-Smith 1976) . Prelimi nary studies with (+ )propranolol in the present ex perimental paradigm failed to show a signiftcant an tagonism of the hyperactivity produced by RU 24969, suggesting that the 5-HTIB receptor may be the site at which locomotor activity is increased by RU 24969. Nevertheless, further studies using converging mea sures will be needed to clarify the somewhat enigmatic interactions between RU 24969 and the isomers of pro pranolol.
There is evidence that the DA system plays a sec ondary role in the expression of behavioral activation induced by RU 24969 (Green et al. 1984; Tricklebank et al. 1986; Uchitomi and Yamawaki 1988) . Although RU 24969 has negligible affmity for catecholamine recep tors, evidence that hyperactivity is eliminated by reser pine but not parachlorophenylalanine or 5,7 -dihydroxy tryptamine suggests that intact catecholamine systems are required for the full expression of RU 24969-induced hyperactivity (Tricklebank et al. 1986 ). The DA an tagonist haloperidol partially inhibits the increased horizontal locomotion induced by RU 24969 (Ober lander and Boissier 1981; Green et al. 1984; Kennett et al. 1987) . However, recent evidence has demonstrated that lesions of the globus pallidus, which disrupt the output of dopaminergic systems and decrease the effect of amphetamine, potentiate the locomotor hyperactivity induced by RU 24969 and preclude the ability of even high doses of haloperidol to antagonize RU 24969-induced hyperactivity (Oberlander et al. 1986 ). These results strongly suggest that the hyperactivity produced by RU 24969 is not mediated directly via dopaminergic neurons. Instead, Oberlander et al. (1986) concluded that RU 24969 acts postsynaptically at a 5-HT receptor to activate the motor system via an influence that is par allel to, rather than sequential with, the DA system. In summary, the present studies demonstrate both qualitative and pharmacologic similarities in the be havioral profiles induced by MDMA and RU 24969. Both the 5-HTIB agonist and the 5-HT-releasing agents pro duce marked increases in repetitive patterns of forward locomotion together with dose-related decreases in in vestigatory holepokes and rearings. In both cases, the hyperactivity but not the decreased investigatory be havior is blocked by racemic propranolol. These results are consistent with the hypothesis that the hyperactivity associated with indirect 5-HT agonists is mediated by the activation of postsynaptic 5-HTlB receptors.
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